New Hope For Advanced PC

Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the 2015 Genitourinary Cancers Symposium.

30 patients with metastatic castration-resistant prostate cancer (mCRPC) were enrolled in the Phase 1 combination study. At the time of enrollment docetaxel was the only FDA-approved treatment that improved overall survival. The median predicted overall survival (OS) was 18.5 months. Patients were treated with PROSTVAC plus escalating doses of ipilimumab. The observed median OS was 31.3 months for all dose cohorts and 37.2 months for patients treated at 10 mg/kg based on updated overall survival data. Furthermore, approximately 20% of patients at 10 mg/kg remain alive at 80 months....

Immunotherapy seems to be where the big breakthroughs are coming from..

Here is the link: news.morningstar.com/all/globe-news-wire/10121616/bavarian-nordic-announces-updated-overall-survival-data-from-combination-immunotherapy-data-of-prostvac-plus-ipilimumab-at-the-2015-genitourinary-cancers-symposium.aspx

Fairwind - thanks for posting this! Immunotherapy coming soon to your neighborhood! It does sound promising. Hopefully someone on this forum will know more about this.

Huge news !! If we all hang on long enough for new treatments, I am pretty convinced that we will die from old age vs. PC

Thanks for the info Fairwind, fortunately I've not progressed there yet but I have a good friend that has. He has printed this out and will be taking your clip to his oncologist meeting next week.

Thanks again to you and others for sifting through the vast info/trials and posting very important progress.

Jake

Beth, I hope Gary has really good success with his treatment too!